Patents Examined by Karen Cochrane Carlson
  • Patent number: 11597894
    Abstract: The present disclosure relates to detergent compositions comprising subtilase variants exhibiting improved stability and/or improved wash performance in liquid detergent and methods for obtaining such detergent compositions. The variants are suitable for use in e.g. cleaning or detergent compositions, such as laundry detergent compositions and dish wash compositions, including automatic dish wash compositions.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: March 7, 2023
    Assignee: Henkel AG & Co. KGaA
    Inventors: Timothy O'Connell, Susanne Tondera, Hendrik Hellmuth, Thomas Weber, Rolf Thomas Lenhard, Signe Eskildsen Larsen, Miguel Duarte Guilherme Pereira Toscano, Esben Peter Friis, Astrid Munch, Mikael Bauer, Bena-Marie Lue
  • Patent number: 11579149
    Abstract: Bioluminescent biosensors useful for monitoring and/or quantifying, in vitro or in vivo, activity of the Hippo signaling pathway. The biosensors monitor LATS kinase activity or YAP-TEAD interaction. The biosensors may be used in methods for monitoring and/or quantifying in real-time, in vitro or in vivo, activity of the Hippo signaling pathway, wherein the activity may be LATS kinase activity and/or YAP-TEAD interaction. The biosensors may be provided in kits for monitoring and/or quantifying in real-time, in vitro or in vivo, activity of the Hippo signaling pathway, wherein the activity may be LATS kinase activity and/or YAP-TEAD interaction.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: February 14, 2023
    Assignee: Queen's University at Kingston
    Inventors: Xiaolong Yang, Taha Azad, Kazem Nouri
  • Patent number: 11578343
    Abstract: Some aspects of this disclosure provide compositions, methods, systems, and kits for controlling the activity of RNA-programmable endonucleases, such as Cas9, or for controlling the activity of proteins comprising a Cas9 variant fused to a functional effector domain, such as a nuclease, nickase, recombinase, deaminase, transcriptional activator, transcriptional repressor, or epigenetic modifying domain. For example, the inventive proteins provided comprise a ligand-dependent intein, the presence of which inhibits one or more activities of the protein (e.g., gRNA binding, enzymatic activity, target DNA binding). The binding of a ligand to the intein results in self-excision of the intein, restoring the activity of the protein.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: February 14, 2023
    Assignee: President and Fellows of Harvard College
    Inventors: David R. Liu, Kevin Davis
  • Patent number: 11572547
    Abstract: The present invention relates to fusion proteins which are capable of binding to phosphatidylserine comprising a phosphatidylserene binding ligand and a modified O6-alkylguanine-DNA alkyltransferase which is capable of autoconjugation to an O6-benzylguanine-modified label, the fusion proteins being capable of binding to phosphatidylserine on the surface of a cell undergoing apoptosis. The invention also relates to recombinant polypeptide precursors of the fusion proteins which comprise a secretion leader sequence, purification tag, protease cleavage site and the fusion protein. Also included in the scope of the invention are nucleic acids encoding the recombinant polypeptide precursor, vectors comprising the nucleic acids, host cells comprising the vectors, methods of production of the fusion proteins, kits and assays for detecting apoptosis.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: February 7, 2023
    Inventors: Eden Padayachee, Fleury Augustin Nsole Biteghe, Olusiji Alex Akinrinmade, Sandra Jordaan, Stefan Barth
  • Patent number: 11559606
    Abstract: Methods and compositions for tissue regeneration of the present invention include a biocompatible porous composite of a decellularized tissue and an aptamer-functionalized hydrogel, wherein the aptamers of the aptamer-functionalized hydrogel specifically and reversibly bind to an active agent.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: January 24, 2023
    Assignee: The Penn State Research Foundation
    Inventors: Yong Wang, Xiaolong Zhang, Nan Zhao
  • Patent number: 11560578
    Abstract: Disclosed are methods for converting a first morphinan alkaloid compound into a second morphinan alkaloid compound in the presence of a neopinone isomerase enzyme under reaction conditions permitting the conversion of the first alkaloid compound into the second alkaloid compound. The first alkaloid compound can be neopinone or neomorphinone. The second alkaloid compound can be codeinone or morphinone. Related compositions are also disclosed.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: January 24, 2023
    Assignee: Antheia, Inc.
    Inventors: Peter J. Facchini, Xue Chen
  • Patent number: 11549104
    Abstract: The present invention relates to polypeptides having beta-glucanase activity, catalytic domains, beta-glucan binding domains and polynucleotides encoding the polypeptides, catalytic domains or beta-glucan binding domains. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or beta-glucan binding domains. The invention further relates to cleaning or detergent compositions comprising polypeptides exhibiting beta-glucanase activity and one or more amylases and/or one or more proteases and uses thereof in cleaning or detergent applications and processes such as cleaning hard-surfaces, dish wash and laundering.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: January 10, 2023
    Assignee: NOVOZYMES A/S
    Inventors: Iben Damager, Morten Gjermansen, Carsten Andersen, Thomas Weber, Inga Kerstin Vockenroth, Clarissa Maisey, Astrid Spitz, Lisa-Marie Schütz, Claudia Ottow, Daniela Herbst, Claudia Lindner
  • Patent number: 11542523
    Abstract: An object of the present invention is to provide an animal cell with improved proliferation ability and survival rate, a method for producing the animal cell, and a method for producing a target protein formed of the animal cell. According to the present invention, there is provided an animal cell having a gene encoding a target protein and a foreign gene encoding an isovaleryl-CoA dehydrogenase, in which the isovaleryl-CoA dehydrogenase is overexpressed.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: January 3, 2023
    Assignee: FUJIFILM Corporation
    Inventors: Tatsuya Matsuura, Tsukasa Ishihara
  • Patent number: 11542305
    Abstract: Disclosed herein include methods, compositions, and kits suitable for use in detecting the activation level of a signal transducer. In some embodiments, there are provided synthetic protein circuits wherein recruitment of synthetic protein circuit components to an association location upon activation of a signal transducer generates an active effector protein. The effector protein can be configured to carry out a variety of functions when in an active state, such as, for example, inducing cell death. Methods of treating a disease or disorder characterized by aberrant signaling are provided in some embodiments.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: January 3, 2023
    Assignee: California Institute of Technology
    Inventors: Xiaojing Gao, Michael B. Elowitz
  • Patent number: 11534467
    Abstract: The invention encompasses compositions, kits and methods for modifying bacteria, preferably naturally occurring bacteria, in situ. These can be used to treat, prevent or cure microbiome-associated diseases or disorders by modulating the molecules expressed and/or secreted by bacterial populations of the microbiome in a specific manner. The genomic modifications can modify the interactions between part or all of these populations and the host in a way that decreases their deleterious potential on host health. The compositions, kits and methods of the invention do not result in the direct death of these populations or a direct significant inhibition of their growth. The invention further includes methods for screening for genetic modifications in the bacteria, for determining the efficiency of vectors at inducing these genetic mutations, and for determining the effects of these mutations on bacterial growth.
    Type: Grant
    Filed: April 8, 2022
    Date of Patent: December 27, 2022
    Assignee: Eligo Bioscience
    Inventors: Xavier Duportet, Antoine Decrulle, Cristina Del Carmen Gil-Cruz, Christian Ivan Pérez-Shibayama, Burkhard Ludewig, Jesus Fernandez Rodriguez, Andreas Brodel
  • Patent number: 11530431
    Abstract: Methods for recombinant production of steviol glycoside and compositions containing steviol glycosides are provided by this invention.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: December 20, 2022
    Assignee: EVOLVA SA
    Inventors: Michael Dalgaard Mikkelsen, Jorgen Hansen, Ernesto Simon, Federico Brianza, Angelika Semmler, Kim Olsson, Simon Carlsen, Louis Düring, Alexei Ouspenski, Paula Hicks
  • Patent number: 11530403
    Abstract: The present invention discloses rapid and cost-effective method of de-glycosyation of a glycoprotein, wherein, glycoprotein is combined with anionic surfactant and reducing agent and non-ionic surfactant in order to obtain stable denatured glycoprotein. An endoglycosidase is further added to denatured glycoprotein to cleave N-linked glycans in order to obtain de-glycosylated protein. A rapid tool for assessing the protein conformation by partial de-glycosylation is also presented wherein the partial de-glycosylated protein is analysed using capillary electrophoresis (CE-SDS).
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: December 20, 2022
    Assignee: BIOCON LIMITED
    Inventors: Anushikha Thakur, Seija Rohil, Shrivardhan Patil, Meenakshi Sudhakaran, Laxmi Adhikary
  • Patent number: 11525148
    Abstract: This document relates to using bidirectional, multi-enzymatic scaffolds to biosynthesize cannabinoids in recombinant hosts.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: December 13, 2022
    Assignee: Khona Scientific Holdings, Inc.
    Inventor: Jordan Buck
  • Patent number: 11499149
    Abstract: The present disclosure provides improved multiplex genome editing compositions and methods. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of a hemoglobinopathy, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: November 15, 2022
    Assignee: 2seventy bio, Inc.
    Inventors: Baeckseung Lee, Alexander Astrakhan
  • Patent number: 11485760
    Abstract: Cas9-inhibiting polypeptide compositions and methods are provided.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: November 1, 2022
    Assignee: The Regents of the University of California
    Inventors: Joseph Bondy-Denomy, Benjamin Rauch
  • Patent number: 11485773
    Abstract: A genetically engineered live bacterium which is adapted to selectively replicate in and colonize a selected tissue type within the mammal, and concurrently produce within the selected tissue type at least one protease-sensitive cytotoxic molecule which is degradable by proteases within the selected tissue type, and at least one protease inhibitor peptide to inhibit the proteases within the selected tissue type from proteolytically degrading the protease sensitive cytotoxic molecule. The combination results in higher concentrations of the cytotoxic molecule local to the colonization, while permitting protease degradation of the cytotoxic molecule further away from the colonization.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: November 1, 2022
    Inventor: David Gordon Bermudes
  • Patent number: 11479792
    Abstract: Provided herein are compositions and methods to make and use engineered cells, for the purpose of increasing the cell density of a culture comprising metazoan cells and for the production of a cultured edible product.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: October 25, 2022
    Assignee: Upside Foods, Inc.
    Inventors: Nicholas J. Genovese, Eric N. Schulze, Danielle N. Desmet
  • Patent number: 11471494
    Abstract: Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: October 18, 2022
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Jonathan W. Kotula, Vincent M. Isabella, Paul F. Miller, Suman Machinani, Saurabh Saha, Adam B. Fisher, Yves Millet, Ning Li, Jose M. Lora
  • Patent number: 11466056
    Abstract: The present invention is directed to a recombinant herpesvirus comprising a heterologous peptide and optionally polypeptide ligand capable of binding to (a) target molecule(s) and fused to or inserted into glycoprotein D. The recombinant herpesvirus may additionally comprise modifications for detargeting the virus from the natural receptors of gD. This allows the herpesvirus to efficiently target a cell for therapeutic purposes and a cell for virus production. The present invention further comprises a pharmaceutical composition comprising the herpesvirus, the herpesvirus for use in the treatment of a tumor, infection, degenerative disorder or senescence-associated disease, a nucleic acid and a vector coding for the gD, a polypeptide comprising the gD, and a cell comprising the herpesvirus, nucleic acid, vector or polypeptide. Moreover, a method for infecting a cell with the herpesvirus or for producing the herpesvirus is disclosed.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: October 11, 2022
    Inventors: Valerio Leoni, Maria Gabriella Campadelli
  • Patent number: 11466069
    Abstract: The present invention provides novels method of targeting delivery of a compound to hypoxic cells, for example treatment of diseases and disorders associated with hypoxia, comprising administration of a construct comprising a targeting carrier peptide and a compound for delivery to a hypoxic cell. The invention also provides novel methods for the treatment of diseases or disorders of the eye by administration of a novel construct, a nucleic acid encoding a novel construct, and/or a nucleic acid vector comprising a nucleic acid encoding a novel construct. The invention further provides novel constructs, nucleic acids encoding such constructs, and/or nucleic acid vectors comprising nucleic acids encoding such constructs.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: October 11, 2022
    Inventors: Colin Richard Green, Frazer Paul Coutinho, Ilva Dana Rupenthal